SCHEMBL4240806

SCHEMBL4240806

CCCCCCCCCCCC(=O)NC(CO)C(O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ASAH2 Q9NR71 1/20 0.64
▸ MAPT P10636 3/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ LMNA P02545 3/20 0.61
▸ CYP3A4 P08684 3/20 0.61
▸ CYP2C19 P33261 3/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ MARS2 Q96GW9 1/20 0.61
▸ TSHR P16473 1/20 0.61
▸ RPLP1 P05386 1/20 0.57
▸ RPLP0 P05388 1/20 0.57
▸ RPS17 P08708 1/20 0.57
▸ RPSA P08865 1/20 0.57
▸ RPS2 P15880 1/20 0.57
▸ RPL35A P18077 1/20 0.57
▸ RPL7 P18124 1/20 0.57
▸ RPL17 P18621 1/20 0.57
▸ RPS4Y1 P22090 1/20 0.57
▸ RPS3 P23396 1/20 0.57
▸ RPS12 P25398 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360962 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL13930323 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL4234491 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL13930313 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL13930315 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL12213638 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL4238306 1.00 ASAH2 (0.64) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL2522862 0.95 ASAH2 (0.59) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL19328599 0.94 ASAH2 (0.58) ASAH2MAPTALDH1A1LMNACYP3A4
SCHEMBL19352897 0.94 ASAH2 (0.58) ASAH2MAPTALDH1A1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054526-A1 INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS UNIVERSITY OF COPENHAGEN (DK) 2009-02-26 — — US claimed
US-20090054526-A1 INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS UNIVERSITY OF COPENHAGEN (DK) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054526-A1 INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS LIPE, PNLIP, FAAH2 ASAH2 17/4885MAPT 4499/4885ALDH1A1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback